Skip to content
lifestyle.inspiredn.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Diakonos Oncology
Diakonos Oncology Awarded Fast Track Designation by FDA for DOC1021 (dubodencel) in Unresectable or Metastatic Cutaneous Melanoma
May 7, 2026
Diakonos Oncology Reports Positive Clinical Data from Phase 1 Pancreatic Cancer Study and Expanded Access Program in Glioblastoma at AACR and AAN 2026
May 3, 2026
/C O R R E C T I O N — Diakonos Oncology/
April 1, 2026
Diakonos Oncology to Showcase DOC1021 (dubodencel) Clinical Data in Pancreatic Cancer and Glioblastoma at AACR and ANN 2026
March 18, 2026
Diakonos Oncology Announces Study to Continue after First DSMB Safety Review of DOC1021 in Phase 2 GBM Study
February 18, 2026